💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

CME Group (CME) Q3 Earnings And Revenues Beat Estimates

Published 10/26/2017, 08:35 AM
Updated 07/09/2023, 06:31 AM
CME
-

Have you been eager to see how CME Group Inc. (NASDAQ:CME) , one of the largest futures exchanges in the world, performed in Q3 in comparison with the market expectations? Let’s quickly scan through the key facts from this Chicago, IL-based company’s earnings release this morning.

An Earnings Beat

CME Group reported adjusted earnings per share of $1.19, beating the Zacks Consensus Estimate of $1.16.

CME Group Inc. Price and EPS Surprise

How Was the Estimate Revision Trend?

You should note that the earnings estimate for CME Group depicted neutral stance prior to the earnings release. The Zacks Consensus Estimate remained unchanged at $1.16 per share over the last 7days.

Also, CME Group has a solid earnings surprise history.

Overall, the company surpassed the Zacks Consensus Estimate by an average of nearly 2.60% in the trailing four quarters.

Revenues Came in Higher Than Expected

CME Group’s revenues of $891 million increased 5.8% year over year. The reported marginally beat the Zacks Consensus Estimate of $890 million.

Key Takeaways

Average daily volume (ADV) increased 10% year over year to a record 15.7 million contracts, with growth across five of the six product lines.

Total expenses increased 2.1% year over year at $322.9 million during the reported quarter.

Operating income improved about 8.1% to $567.9 million from the prior-year quarter.

As of Sep 30, 2017, long-term debt of $2.2 billion inched up 0.1% from 2016 the year-end figure.

What Zacks Rank Says

The estimate revisions that we discussed earlier have driven a Zacks Rank #3(Hold) for CME Group. However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change. Now it all depends on what sense the just-released report makes to the analysts.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Check back later for our full write up on this CME Group earnings report!

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>



CME Group Inc. (CME): Free Stock Analysis Report

Original post

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.